PLASMA PCSK9 AND CARDIOVASCULAR EVENTS IN TYPE 2 DIABETES

被引：0
|
作者：
El Khoury, Petra [1 ,2 ]
Roussel, Ronan [3 ,4 ,5 ]
Fumeron, Frederic [4 ,5 ]
Velho, Gilberto [5 ]
Jacob, Marie-Paule [1 ,4 ]
Steg, Gabriel [1 ,4 ,6 ,7 ]
Potier, L. [3 ,4 ,5 ]
Ghaleb, Youmna [1 ,2 ,4 ]
Elbitar, Sandy [1 ,2 ,4 ]
Abifadel, Marianne [1 ,2 ]
Boileau, Catherine [1 ,4 ,8 ]
Marre, Michel [3 ,4 ,5 ]
Varret, Mathilde [1 ,4 ]
Hansel, Boris [3 ,4 ,5 ]
机构：
[1] INSERM, U1148, Paris, France
[2] St Joseph Univ, Beruth, Lebanon
[3] CHU Bichat, Aphp, Dept Nutr, Paris, France
[4] Denis Diderot Univ Paris 7, Paris, France
[5] INSERM, U1138, Paris, France
[6] CHU Bichat, Aphp, Dept Cardiol, Paris, France
[7] Imperial Coll, NHLI, Royal Brompton Hosp, London, England
[8] CHU Bichat, Aphp, Dept Genet, Paris, France
来源：
ATHEROSCLEROSIS | 2017年 / 263卷
关键词：
D O I：
10.1016/j.atherosclerosis.2017.06.263
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAG142
引用
收藏
页码：E81 / E81
页数：1
相关论文
共 50 条
  • [11] Effect of Physical Activity on Plasma PCSK9 in Subjects With High Risk for Type 2 Diabetes
    Makela, Kari Antero
    Leppaluoto, Juhani
    Jokelainen, Jan
    Jamsa, Timo
    Keinanen-Kiukaanniemi, Sirkka
    Herzig, Karl-Heinz
    FRONTIERS IN PHYSIOLOGY, 2019, 10
  • [12] Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes
    Trico, Domenico
    Raggi, Francesco
    Distaso, Mariarosaria
    Ferrannini, Ele
    Solini, Anna
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 190
  • [13] Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes
    Cariou, B.
    Ramin-Mangata, S.
    Wargny, M.
    Pichelin, M.
    Le May, C.
    Blanchard, V.
    Santos, R.
    Bensenor, I.
    Lotufo, P.
    Lambert, G.
    DIABETOLOGIA, 2019, 62 : S164 - S165
  • [14] Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes
    Ramin-Mangata, Stephane
    Wargny, Matthieu
    Pichelin, Matthieu
    Le May, Cedric
    Thedrez, Aurelie
    Blanchard, Valentin
    Nativel, Brice
    Santos, Raul D.
    Bensenor, Isabela M.
    Lotufo, Paulo A.
    Lambert, Gilles
    Cariou, Bertrand
    ATHEROSCLEROSIS, 2020, 293 : 49 - 56
  • [15] Circulating Pcsk9 Levels Are Not Associated With the Conversion to Type 2 Diabetes
    Ramin-Mangata, Stephane
    Lambert, Gilles
    CIRCULATION, 2019, 140
  • [16] The association between circulatory, local pancreatic PCSK9 and type 2 diabetes mellitus: The effects of antidiabetic drugs on PCSK9
    Lu, Fengyuan
    Li, En
    Yang, Xiaoyu
    HELIYON, 2023, 9 (09)
  • [17] PCSK9 Is Increased in Youth With Type 1 Diabetes
    Levenson, Amy E.
    Wadwa, R. Paul
    Shah, Amy S.
    Khoury, Philip R.
    Kimball, Thomas R.
    Urbina, Elaine M.
    de Ferranti, Sarah D.
    Bishop, Franziska K.
    Maahs, David M.
    Dolan, Lawrence M.
    Biddinger, Sudha B.
    DIABETES CARE, 2017, 40 (07) : E85 - E87
  • [18] Effects of PCSK9 inhibitors on cancer, diabetes, and cardiovascular diseases
    Nejabat, Mojgan
    Hadizadeh, Farzin
    Almahmeed, Wael
    Sahebkar, Amirhossein
    DRUG DISCOVERY TODAY, 2025, 30 (03)
  • [19] Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
    Ference, Brian A.
    Robinson, Jennifer G.
    Brook, Robert D.
    Catapano, Alberico L.
    Chapman, M. John
    Neff, David R.
    Voros, Szilard
    Giugliano, Robert P.
    Smith, George Davey
    Fazio, Sergio
    Sabatine, Marc S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22): : 2144 - 2153
  • [20] PCSK9 and diabetes: is there a link?
    Momtazi, Amir Abbas
    Banach, Maciej
    Pirro, Matteo
    Stein, Evan A.
    Sahebkar, Amirhossein
    DRUG DISCOVERY TODAY, 2017, 22 (06) : 883 - 895
12345